GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:190495122 | Liver | HCC | positive regulation of establishment of protein localization | 207/7958 | 319/18723 | 3.95e-16 | 3.29e-14 | 207 |
GO:00064732 | Liver | HCC | protein acetylation | 135/7958 | 201/18723 | 1.20e-12 | 5.92e-11 | 135 |
GO:00435432 | Liver | HCC | protein acylation | 157/7958 | 243/18723 | 2.40e-12 | 1.12e-10 | 157 |
GO:005149522 | Liver | HCC | positive regulation of cytoskeleton organization | 138/7958 | 226/18723 | 1.26e-08 | 3.12e-07 | 138 |
GO:19021151 | Liver | HCC | regulation of organelle assembly | 110/7958 | 186/18723 | 3.30e-06 | 4.34e-05 | 110 |
GO:004578711 | Liver | HCC | positive regulation of cell cycle | 172/7958 | 313/18723 | 5.29e-06 | 6.58e-05 | 172 |
GO:0031023 | Liver | HCC | microtubule organizing center organization | 82/7958 | 143/18723 | 2.38e-04 | 1.79e-03 | 82 |
GO:0007098 | Liver | HCC | centrosome cycle | 75/7958 | 130/18723 | 3.33e-04 | 2.34e-03 | 75 |
GO:19019831 | Liver | HCC | regulation of protein acetylation | 48/7958 | 77/18723 | 3.49e-04 | 2.43e-03 | 48 |
GO:00900683 | Liver | HCC | positive regulation of cell cycle process | 125/7958 | 236/18723 | 7.21e-04 | 4.40e-03 | 125 |
GO:1902117 | Liver | HCC | positive regulation of organelle assembly | 41/7958 | 67/18723 | 1.55e-03 | 8.20e-03 | 41 |
GO:0032886 | Liver | HCC | regulation of microtubule-based process | 123/7958 | 240/18723 | 3.69e-03 | 1.64e-02 | 123 |
GO:00466052 | Liver | HCC | regulation of centrosome cycle | 30/7958 | 49/18723 | 6.31e-03 | 2.57e-02 | 30 |
GO:1901985 | Liver | HCC | positive regulation of protein acetylation | 27/7958 | 45/18723 | 1.35e-02 | 4.80e-02 | 27 |
GO:1904951113 | Thyroid | PTC | positive regulation of establishment of protein localization | 175/5968 | 319/18723 | 1.10e-17 | 1.12e-15 | 175 |
GO:00064737 | Thyroid | PTC | protein acetylation | 116/5968 | 201/18723 | 3.05e-14 | 1.92e-12 | 116 |
GO:00435437 | Thyroid | PTC | protein acylation | 134/5968 | 243/18723 | 4.22e-14 | 2.58e-12 | 134 |
GO:005149526 | Thyroid | PTC | positive regulation of cytoskeleton organization | 121/5968 | 226/18723 | 1.04e-11 | 4.27e-10 | 121 |
GO:004578718 | Thyroid | PTC | positive regulation of cell cycle | 144/5968 | 313/18723 | 9.93e-08 | 1.99e-06 | 144 |
GO:19019837 | Thyroid | PTC | regulation of protein acetylation | 46/5968 | 77/18723 | 4.26e-07 | 7.03e-06 | 46 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CEP295 | SNV | Missense_Mutation | novel | c.1867N>G | p.Ile623Val | p.I623V | Q9C0D2 | protein_coding | tolerated(0.49) | benign(0.001) | TCGA-4R-AA8I-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
CEP295 | SNV | Missense_Mutation | | c.4463N>A | p.Phe1488Tyr | p.F1488Y | Q9C0D2 | protein_coding | tolerated(0.18) | benign(0.006) | TCGA-DD-A1EG-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Targeted Molecular therapy | sorafenib | PD |
CEP295 | SNV | Missense_Mutation | | c.458C>T | p.Ala153Val | p.A153V | Q9C0D2 | protein_coding | deleterious(0.04) | possibly_damaging(0.728) | TCGA-DD-A73D-01 | Liver | liver hepatocellular carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
CEP295 | SNV | Missense_Mutation | novel | c.7292G>A | p.Cys2431Tyr | p.C2431Y | Q9C0D2 | protein_coding | deleterious(0.01) | benign(0) | TCGA-DD-AACQ-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
CEP295 | SNV | Missense_Mutation | novel | c.4618N>T | p.Arg1540Trp | p.R1540W | Q9C0D2 | protein_coding | deleterious(0) | probably_damaging(0.983) | TCGA-DD-AAW1-01 | Liver | liver hepatocellular carcinoma | Male | <65 | III/IV | Unknown | Unknown | SD |
CEP295 | SNV | Missense_Mutation | | c.7357N>A | p.Val2453Ile | p.V2453I | Q9C0D2 | protein_coding | tolerated(0.49) | benign(0.005) | TCGA-ES-A2HS-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
CEP295 | SNV | Missense_Mutation | novel | c.7294N>G | p.Phe2432Val | p.F2432V | Q9C0D2 | protein_coding | tolerated(0.19) | benign(0.01) | TCGA-LG-A9QD-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | III/IV | Targeted Molecular therapy | sorafenib | SD |
CEP295 | SNV | Missense_Mutation | rs767897172 | c.5846N>G | p.Asp1949Gly | p.D1949G | Q9C0D2 | protein_coding | tolerated(0.09) | benign(0.058) | TCGA-56-6545-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CEP295 | SNV | Missense_Mutation | novel | c.5848N>G | p.Lys1950Glu | p.K1950E | Q9C0D2 | protein_coding | tolerated(0.21) | benign(0.011) | TCGA-CN-A63U-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |